Kalohexis confidentially files IPO to back obesity and cachexia portfolio - Pharmaceutical Technology

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline. The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline. Kalohexis plans to make its public debut as it progresses its range of peptide-based therapeutics for cancer cachexia and obesity through the clinic. Credit: treety / Shutterstock.com. Metabolic health-focused drug developer Kalohexis is eyeing a debut on the public market after confidentially filing for an initial public offering (IPO) – potentially adding it to a growing list of American biotechs that have opted to go public…

Source: Pharmaceutical Technology